ArticleCancer medicine2025
Association Between CD147 Expression, RAS Mutational Status, and Local Recurrence in Resected Locally Advanced Rectal Cancer.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Association Between CD147 Expression, RAS Mutational Status, and Local Recurrence in Resected Locally Advanced Rectal Cancer.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
aimAbout 5% to 10% of rectal cancer (RC) patients experience local disease recurrence after chemoradiotherapy (CRT) and surgery. Identifying patients at high risk of local recurrence (LR) could lead to the personalized management of the patients. Multiple clinicopathological parameters are associated with LR. However, the potential of tumors for local regrowth may partially lie in the expression of pro-tumoral factors and genetic characteristics. In this work, we aimed to evaluate the association of tumor CD147 expression, a well-described cancer aggressiveness biomarker, and mutational status, with post-resection RC LR.
methodsWe retrospectively analyzed all patients experiencing LR after CRT and resection at Bordeaux University Hospital (2010 to 2019) and matched a LR-negative control cohort. CD147 expression was evaluated by immunohistochemistry on post-neoadjuvant treatment residual tumors. Mutational status was assessed by next-generation sequencing. Correlations with LR rates were evaluated.
resultsThe analysis included 29 patients with recurrences and 60 without. The pathological node invasion stage (p = 0.023) and the median number of invaded nodes (p = 0.008) were significantly associated with LR. CD147 expression and mutational status were not associated with LR. Nonetheless, a notable association was observed between RAS mutation and elevated CD147 expression, particularly in male patients (p = 0.005). We confirmed this association in an independent validation cohort of 86 RC patients.
conclusionCD147 tumor expression levels and mutational status do not appear to be associated with resected RC LR. However, the association between RAS mutational status and CD147 expression in male patients tends to confirm the relationship between RAS activating mutations and tumor aggressiveness, as well as their sex-related impact on colorectal tumor biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.